MAGL

MAGL-IN-21 (Compound (S)-6) is a selective inhibitor of monoacylglycerol lipase (MAGL) with an IC50 of 1.59 nM.

MAGL-IN-9, also referred to as compound 16, is a reversible inhibitor of monoacylglycerol lipase (MAGL) with a potent IC50 value of 2.7 nM [1].

MAGL-IN-8 (compound 13) is a reversible inhibitor of monoacylglycerol lipase (MAGL) with an IC50 value of 2.5 ± 0.4 nM for human MAGL (hMAGL) [1].

MAGL-IN-11 (compound 29) is a selective, reversible inhibitor of monoacylglycerol lipase (MAGL) with potential applications in inflammation, cancer, and antioxidant research [1].

MAGL-IN-10, a reversible monoacylglycerol lipase (MAGL) inhibitor, exhibits favorable ADME properties and low in vivo toxicity. It is applicable in the study of cancer, neurological disorders, and inflammatory pathologies [1].

MAGL-IN-18 (compound 118) serves as a highly potent inhibitor of Monoacylglycerol lipase (MAGL), demonstrating an IC 50 value of 0.03nM.

MAGL-IN-20 (compound ±34) is a reversible inhibitor of monoacylglycerol lipase (MAGL). It exhibits significant antiproliferative activity against a range of cancer cell lines, including H460, HT29, CT-26, Huh7, and HCCLM-3.

MAGL-IN-1 is a selective and potent monoacylglycerol lipase (MAGL) inhibitor with an IC50 of 80 nM.

MAGL-IN-19 (compound 7o) is a highly effective and selective inhibitor of MAGL.

FAAH MAGL-IN-1, also known as compound SIH 3, is a highly effective inhibitor of FAAH (fatty acid amide hydrolase) and MAGL (monoacylglycerol lipase). It exhibits IC50 values of 31 nM and 29 nM against FAAH and MAGL, respectively. This compound shows promising potential for advancing research in the field of neuropathic pain [1].

FAAH MAGL-IN-2, a potent and reversible inhibitor of FAAH and MAGL, demonstrates oral activity and the ability to cross the blood-brain barrier. It exhibits IC50 values of 11 nM for FAAH and 36 nM for MAGL (Ki values of 28 nM and 60 nM, respectively). This compound shows promise for neuropathic pain research, without impairing locomotion [1].

MAGL-IN-6, a potent inhibitor of MAGL (IC50: 4.71 nM), can be utilized for studying neurological diseases.

FAAH MAGL-IN-3 (Compound 10) is an irreversible dual inhibitor of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) with an IC50 of 179 nM for FAAH and 759 nM for MAGL. FAAH MAGL-IN-3 exhibited minimal permeability in the PAMPA (parallel artificial membrane permeability assay).

MAGL-IN-14 (compound 2) serves as a potent MAGL inhibitor, exhibiting IC50 values of 0.00289 μM in HEK293 cells and 0.002 μM in PC3 cells [1].

MAGL-IN-15 (Compound 6), a MAGL inhibitor, holds potential for research into diseases and disorders associated with the regulation of endocannabinoid system signaling activities [1].

MAGL-IN-4 (His121 ARG57) is one of the monoacylglycerol lipase (MAGL) inhibitors in central nervous system-related diseases.

MAGL-IN-5 is a non-selective lipase inhibitor.

Semaglutide is a glucagon-like peptide 1 receptor (GLP-1R) agonist(EC50 of 6.2 pM in a reporter assay using BHK cells expressing the human receptor).

Semaglutide Acetate is an agonist of a glucagon-like peptide 1 (GLP-1) receptor and can be used in studies about the treatment of type 2 diabetes.

MAGLi 432 is a potent, highly selective, non-covalent, reversible (MAGL) inhibitor that binds with high affinity to the MAGL active site, with IC50 values of 4.2 nM (human enzyme) and 3.1 nM (mouse enzyme), MAGLi 432 can be used to study neurological disorders such as chronic inflammation, multiple sclerosis, blood-brain barrier dysfunction, Alzheimer's disease and Parkinson's disease.

LY2140023 has the potential for schizophrenia.LY2140023 is an orally active prodrug of LY404039. LY404039 is a selective metabotropic glutamate 2 3 receptor agonist.

Pomaglumetad methionil is an oral methionine prodrug of the potent specific agonist of mGlu2 3 receptor LY404039.

Semaglutide TFA is a glucagon-like peptide-1 congener that induces weight loss, lowers blood glucose levels, and reduces cardiovascular risk in diabetic patients.Semaglutide TFA induces mild-to-moderate and transient gastrointestinal disturbances, and may be used in the study of type 2 diabetes and obesity.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. This compound mimics GLP-1 to lower blood glucose levels and stimulates the growth of pancreatic β-cells responsible for insulin production and release. Additionally, Semaglutide inhibits the production of glucagon, a hormone that enhances glycogenolysis [the release of liver-stored carbohydrates] and gluconeogenesis [the synthesis of new glucose]. By reducing appetite and slowing gastric emptying, it also helps decrease food intake and aids in reducing body fat.